Ordering
Available Variants5 mg
CHA.26879-5mg
Price
€143.20
Available – Dispatch in 14 days
25 mg
CHA.26879-25mg
Price
€550.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.26879-5mg | €143.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.26879-25mg | €550.40 |
≥98% (HPLC), CDK and CDC25 phosphatase family inhibitor, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C21H20ClNO5 ·HCl · xH2O |
|---|---|
| CAS Number | 131740-09-5 |
| Molecular Weight | 438.30 (anhydrous basis) |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 24724481 |
| NACRES | NA.77 |
| MDL number | MFCD26792554 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Gloves |
Technical Overview & Applications Use-case context
Flavopiridol hydrochloride hydrate, with a CAS number of 131740-09-5, is a synthetic flavone derivative that has garnered significant attention in the realm of pharmacology and oncology. This compound exhibits potent inhibitory effects on various cyclin-dependent kinases, which are crucial regulators of the cell cycle. By inhibiting these kinases, flavopiridol hydrochloride hydrate induces cell cycle arrest and apoptosis in cancer cells, thereby exerting its anti-tumor activity. The hydrate form of this compound is particularly notable for its enhanced solubility and stability, making it a valuable candidate for further research and development. Studies have demonstrated the efficacy of flavopiridol hydrochloride hydrate in targeting a range of cancers, including leukemia, breast cancer, and lung cancer, highlighting its potential as a therapeutic agent in the treatment of these diseases.
